Søgeord (hepatitis) valgt.
30 emner vises.
1
Hepatitis Kills 3.5 Million People Each Day, Says WHO
Medscape Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Although annual incidence decreased from 2.5 million in 2019 to 2.2 million in 2022, the WHO considers it to be high. Medscape Medical News
Læs mere
2
Hepatitis E Vaccine Shows Long-Term Efficacy
Medscape Infectious Diseases, 8.04.2024
Tilføjet 8.04.2024
While the hepatitis E virus causes tens of thousands of deaths each year, data suggest that a vaccine approved in China has long-term efficacy. Medscape Medical News
Læs mere
3
Communicable disease threats report, 17-23 March 2024, week 12
ECDC
ECDC COVID-19 updates, 22.03.2024
Tilføjet 22.03.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 17-23 March 2024 and includes updates on SARS-CoV-2 variant classification, hepatitis A, pertussis, invasive Group A streptococcal infection, chikungunya, dengue, poliomyelitis, western equine encephalitis and cholera.
Læs mere
4
Communicable disease threats report, 17-23 March 2024, week 12
ECDC
ECDC Communicable Disease Threats Report, 22.03.2024
Tilføjet 22.03.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 17-23 March 2024 and includes updates on SARS-CoV-2 variant classification, hepatitis A, pertussis, invasive Group A streptococcal infection, chikungunya, dengue, poliomyelitis, western equine encephalitis and cholera.
Læs mere
5
Hepatitis A Exposure Response and Outbreak Prevention in a Large Urban Jail - Los Angeles County, California, May-July 2023
Morbidity and Mortality Weekly Report (MMWR), 16.02.2024
Tilføjet 16.02.2024
This report describes Correctional Health Services and LA County Jail\'s response to a confirmed case of Hepatitis A in a person who is incarcerated.
Læs mere
6
Communicable disease threats report, 4-10 February 2024, week 6
ECDC
ECDC Communicable Disease Threats Report, 9.02.2024
Tilføjet 9.02.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 4-10 February 2024 and includes updates on avian influenza, measles, MERS-CoV, COVID-19, swine influenza, respiratory virus epidemiology, Western equine encephalitis, Hepatitis E, and the Chinese New Year.
Læs mere
7
Communicable disease threats report, 4-10 February 2024, week 6
ECDC
ECDC COVID-19 updates, 9.02.2024
Tilføjet 9.02.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 4-10 February 2024 and includes updates on avian influenza, measles, MERS-CoV, COVID-19, swine influenza, respiratory virus epidemiology, Western equine encephalitis, Hepatitis E, and the Chinese New Year.
Læs mere
8
Communicable disease threats report, 17-23 December 2023, week 51
ECDC
ECDC COVID-19 updates, 23.12.2023
Tilføjet 23.12.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 17-23 December 2023 and includes updates on cholera, SARS-CoV-2 variant classification, avian influenza in fur farms, hepatitis A, pertussis, a cluster of extensively drug-resistant Shigella Sonnei among men who have sex with men, and an overview of respiratory virus epidemiology in the EU/EE.
Læs mere
9
Communicable disease threats report, 17-23 December 2023, week 51
ECDC
ECDC Communicable Disease Threats Report, 22.12.2023
Tilføjet 22.12.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 17-23 December 2023 and includes updates on cholera, SARS-CoV-2 variant classification, avian influenza in fur farms, hepatitis A, pertussis, a cluster of extensively drug-resistant Shigella Sonnei among men who have sex with men, and an overview of respiratory virus epidemiology in the EU/EE.
Læs mere
10
Patients Exposed to HIV, Hepatitis at Salem Hospital
Medscape Infectious Diseases, 1.12.2023
Tilføjet 1.12.2023
At least 450 patients at Mass General Brigham, Salem Hospital, near Boston are at risk of HIV and hepatitis infection, according to a lawsuit claiming negligent intravenous medication administration. Medscape Medical News
Læs mere
11
The Remaining Frontiers in Fighting Hepatitis C
Medscape Infectious Diseases, 11.11.2023
Tilføjet 11.11.2023
A scientist whose work was key to identifying, studying, and finding treatments for this life-threatening virus discusses the scientific journey and challenges that persist. Knowable Magazine
Læs mere
12
RECOMMENDATIONS AND REPORTS: CDC Recommendations for Hepatitis C Testing Among Perinatally Exposed Infants and Children - United States, 2023
Morbidity and Mortality Weekly Report (MMWR), 1.11.2023
Tilføjet 1.11.2023
CDC reports on CDC recommendations for hepatitis C testing among perinatally exposed infants and children in the United States in 2023.
Læs mere
13
A War on Another Front: Ukraine's Fight Against Hepatitis C
Medscape Infectious Diseases, 20.10.2023
Tilføjet 20.10.2023
Despite ongoing hostilities, healthcare professionals take mobile clinics to their fellow Ukrainians, as the battle extends to fighting the country\'s high levels of hepatitis C. Medscape Medical News
Læs mere
14
Preventable Deaths During Widespread Community Hepatitis A Outbreaks - United States, 2016-2022
Morbidity and Mortality Weekly Report (MMWR), 19.10.2023
Tilføjet 19.10.2023
This report describes deaths related to hepatitis A outbreaks.
Læs mere
15
Communicable disease threats report, 8-14 October 2023, week 41
ECDC
ECDC Communicable Disease Threats Report, 13.10.2023
Tilføjet 13.10.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 8-14 October 2023 and includes updates on hepatitis A, influenza A(H5N1), COVID-19, the Rugby World Cup 2023, West Nile virus, measles and diphtheria.
Læs mere
16
Communicable disease threats report, 8-14 October 2023, week 41
ECDC
ECDC COVID-19 updates, 13.10.2023
Tilføjet 13.10.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 8-14 October 2023 and includes updates on hepatitis A, influenza A(H5N1), COVID-19, the Rugby World Cup 2023, West Nile virus, measles and diphtheria.
Læs mere
17
Epidemiology of common infectious diseases before and during the COVID-19 pandemic in Bavaria, Germany, 2016 to 2021: an analysis of routine surveillance data
Sarah van de Berg, Tanja Charles, Achim Dörre, Katharina Katz and Stefanie Böhm
Eurosurveillance latest updates, 13.10.2023
Tilføjet 13.10.2023
BackgroundUnprecedented non-pharmaceutical interventions to control the COVID-19 pandemic also had an effect on other infectious diseases. AimWe aimed to determine their impact on transmission and diagnosis of notifiable diseases other than COVID-19 in Bavaria, Germany, in 2020 and 2021. MethodsWe compared weekly cases of 15 notifiable infectious diseases recorded in Bavaria between 1 January 2016 and 31 December 2021 in time series analyses, median age and time-to-diagnosis using Wilcoxon rank sum test and hospitalisation rates using univariable logistic regression during three time periods: pre-pandemic (weeks 1 2016–9 2020), pandemic years 1 (weeks 10–52 2020) and 2 (2021). ResultsWeekly case numbers decreased in pandemic year 1 for all diseases assessed except influenza, Lyme disease and tick-borne encephalitis; markedly for norovirus gastroenteritis (IRR = 0.15; 95% CI: 0.12–0.20) and pertussis (IRR = 0.22; 95% CI: 0.18–0.26). In pandemic year 2, influenza (IRR = 0.04; 95% CI: 0.02–0.09) and pertussis (IRR = 0.11; 95% CI: 0.09–0.14) decreased markedly, but also chickenpox, dengue fever, Haemophilus influenzae invasive infection, hepatitis C, legionellosis, noro- and rotavirus gastroenteritis and salmonellosis. For enterohaemorrhagic Escherichia coli infections, median age decreased in pandemic years 1 and 2 (4 years, interquartile range (IQR): 1–32 and 3 years, IQR: 1–18 vs 11 years, IQR: 2–42); hospitalisation proportions increased in pandemic year 1 (OR = 1.60; 95% CI: 1.08–2.34). ConclusionReductions for various infectious diseases and changes in case characteristics in 2020 and 2021 indicate reduced transmission of notifiable diseases other than COVID-19 due to interventions and under-detection.
Læs mere
18
No Need to Restrict Hep C DAA Therapy Based on Alcohol Use
Medscape Infectious Diseases, 27.09.2023
Tilføjet 27.09.2023
Alcohol use at any level was not associated with a lower likelihood of responding to direct-acting antiviral therapy for chronic hepatitis C virus infection. Medscape Medical News
Læs mere
19
Task Force for a rapid response to an outbreak of severe acute hepatitis of unknown aetiology in children in Portugal in 2022
Berta Grau-Pujol, João Vieira Martins, Isabel Goncalves, Fernanda Rodrigues, Rita de Sousa, Dina Oliveira, Joana Bettencourt, Diana Mendes, Inês Mateus de Cunha, Sara Pocinho, Ana Firme, Benvinda Estela dos Santos, André Peralta Santos, Maria João Albuquerque, Pedro Pinto-Leite, Rui Tato Marinho and Paula Vasconcelos
Eurosurveillance latest updates, 22.09.2023
Tilføjet 22.09.2023
On 5 April 2022, the United Kingdom reported an increase of cases of severe acute hepatitis of unknown aetiology in children, several needing hospitalisation and some required liver transplant or died. Thereafter, 35 countries reported probable cases, almost half of them in Europe. Facing the alert, on 28 April, Portugal created a multidisciplinary Task Force (TF) for rapid detection of probable cases and response. The experts of the TF came from various disciplines: clinicians, laboratory experts, epidemiologists, public health experts and national and international communication. Moreover, Portugal adopted the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO) case definition and recommendations. By 31 December 2022, 28 probable cases of severe acute hepatitis of unknown aetiology were reported: 16 male and 17 aged under 2 years. Of these cases, 23 were hospitalised but none required liver transplant or died. Adenovirus was detected from nine of 26 tested cases. No association was observed between adenovirus infection and hospital admission after adjusting for age, sex and region in a binomial regression model. The TF in Portugal may have contributed to increase awareness among clinicians, enabling early detection and prompt management of the outbreak.
Læs mere
20
Mortality Rates Remain High After Hepatitis C Cure
Medscape Infectious Diseases, 23.08.2023
Tilføjet 23.08.2023
Mortality rates remain substantially elevated after successful treatment of hepatitis C infection in the era of interferon-free antiviral therapy, a study of over 20,000 patients has found. Medscape Medical News
Læs mere
21
Estimates of hepatitis B virus prevalence among general population and key risk groups in EU/EEA/UK countries: a systematic review
Sandra Bivegete, Anna L McNaughton, Adam Trickey, Zak Thornton, Becky Scanlan, Aaron G Lim, Lina Nerlander, Hannah Fraser, Josephine G Walker, Matthew Hickman, Peter Vickerman, Helen Johnson, Erika Duffell, Ellen Brooks-Pollock and Hannah Christensen
Eurosurveillance latest updates, 28.07.2023
Tilføjet 28.07.2023
BackgroundThe burden of chronic hepatitis B virus (HBV) varies across the European Union (EU) and European Economic Area (EEA). AimWe aimed to update the 2017 HBV prevalence estimates in EU/EEA countries and the United Kingdom for 2018 to 2021. MethodsWe undertook a systematic review, adding to HBV prevalence estimates from an existing (2005–2017) database. Databases were searched for original English-language research articles including HBV surface antigen prevalence estimates among the general population, pregnant women, first-time blood donors (FTB), men who have sex with men (MSM), migrants and people in prison. Country experts contributed grey literature data. Risk of bias was assessed using a quality assessment framework. FindingsThe update provided 147 new prevalence estimates across the region (updated total n = 579). Median HBV prevalence in the general population was 0.5% and the highest was 3.8% (Greece). Among FTB, the highest prevalence was 0.8% (Lithuania). Estimates among pregnant women were highest in Romania and Italy (5.1%). Among migrants, the highest estimate was 31.7% (Spain). Relative to 2017 estimates, median prevalence among pregnant women decreased by 0.5% (to 0.3%) and increased by 0.9% (to 5.8%) among migrants. Among MSM, the highest estimate was 3.4% (Croatia). Prevalence among people in prison was highest in Greece (8.3%) and the median prevalence increased by 0.6% (to 2.1%). ConclusionsThe HBV prevalence is low in the general population and confined to risk populations in most European countries with some exceptions. Screening and treatment should be targeted to people in prison and migrants.
Læs mere
22
Toward reaching hepatitis B goals: hepatitis B epidemiology and the impact of two decades of vaccination, Georgia, 2021
Nino Khetsuriani, Amiran Gamkrelidze, Shaun Shadaker, Maia Tsereteli, Maia Alkhazashvili, Nazibrola Chitadze, Irina Tskhomelidze, Lia Gvinjilia, Francisco Averhoff, Gavin Cloherty, Qian An, Giorgi Chakhunashvili, Jan Drobeniuc, Paata Imnadze, Khatuna Zakhashvili and Paige A Armstrong
Eurosurveillance latest updates, 28.07.2023
Tilføjet 28.07.2023
BackgroundGeorgia has adopted the World Health Organization European Region’s and global goals to eliminate viral hepatitis. A nationwide serosurvey among adults in 2015 showed 2.9% prevalence for hepatitis B virus (HBV) surface antigen (HBsAg) and 25.9% for antibodies against HBV core antigen (anti-HBc). HBV infection prevalence among children had previously not been assessed. AimWe aimed to assess HBV infection prevalence among children and update estimates for adults in Georgia. MethodsThis nationwide cross-sectional serosurvey conducted in 2021 among persons aged ≥ 5 years used multi-stage stratified cluster design. Participants aged 5–20 years were eligible for hepatitis B vaccination as infants. Blood samples were tested for anti-HBc and, if positive, for HBsAg. Weighted proportions and 95% confidence intervals (CI) were calculated for both markers. ResultsAmong 5–17 year-olds (n = 1,473), 0.03% (95% CI: 0–0.19) were HBsAg-positive and 0.7% (95% CI: 0.3–1.6) were anti-HBc-positive. Among adults (n = 7,237), 2.7% (95% CI: 2.3–3.4) were HBsAg-positive and 21.7% (95% CI: 20.4–23.2) anti-HBc-positive; HBsAg prevalence was lowest (0.2%; 95% CI: 0.0–1.5) among 18–23-year-olds and highest (8.6%; 95% CI: 6.1–12.1) among 35–39-year-olds. ConclusionsHepatitis B vaccination in Georgia had remarkable impact. In 2021, HBsAg prevalence among children was well below the 0.5% hepatitis B control target of the European Region and met the ≤ 0.1% HBsAg seroprevalence target for elimination of mother-to-child transmission of HBV. Chronic HBV infection remains a problem among adults born before vaccine introduction. Screening, treatment and preventive interventions among adults, and sustained high immunisation coverage among children, can help eliminate hepatitis B in Georgia by 2030.
Læs mere
23
Insights from a national survey in 2021 and from modelling on progress towards hepatitis C virus elimination in the country of Georgia since 2015
Josephine G. Walker, Irina Tskhomelidze, Shaun Shadaker, Maia Tsereteli, Senad Handanagic, Paige A. Armstrong, Amiran Gamkrelidze and Peter Vickerman
Eurosurveillance latest updates, 28.07.2023
Tilføjet 28.07.2023
BackgroundBetween May 2015 and February 2022, 77,168 hepatitis C virus (HCV)-infected people in Georgia have been treated through an HCV elimination programme. To project the programme’s long-term impacts, an HCV infection model was initially developed, based on data from surveys among people who inject drugs and a national serosurvey in 2015. AimAccounting for follow-up surveys in 2021, we validate and update projections of HCV infection prevalence and incidence. MethodWe assessed the initial model projections’ accuracy for overall prevalence, by age, sex, and among people who ever injected drugs, compared with 2021 serosurvey data. We used 2021 results to weight model fits and to recalculate the national programme’s impact leading up to March 2022 on HCV infection incidence rates. Cases and deaths averted were estimated. The impact of reduced treatment rates during the COVID-19 pandemic was assessed. ResultsThe original model overpredicted adult (≥ 18 years old) chronic HCV infection prevalence for 2021 (2.7%; 95% credible interval (CrI): 1.9–3.5%) compared with a 2021 serosurvey (1.8%; 95% confidence interval (CI): 1.3–2.4%). Weighted model projections estimated a 60% decrease in HCV infection incidence by March 2022, with an absolute incidence of 66 (95% CrI: 34–131) per 100,000 person-years (overall population). Between May 2015 and March 2022, 9,186 (95% CrI: 5,396–16,720) infections and 842 (95% CrI: 489–1,324) deaths were averted. The COVID-19 pandemic resulted in 13,344 (95% CrI: 13,236–13,437) fewer treatments and 438 (95% CrI: 223-744) fewer averted infections by March 2022. ConclusionResults support the programme’s high effectiveness. At current treatment rate (406/month), 90% reductions in prevalence and incidence in Georgia are achievable by 2030.
Læs mere
24
Two-Pronged Approach Needed in Alcohol-Associated Hepatitis
Medscape Infectious Diseases, 28.07.2023
Tilføjet 28.07.2023
Managing alcohol-associated hepatitis following hospital discharge requires treating not only the liver disease but also the underlying alcohol use disorder, says a clinical care review. Medscape Medical News
Læs mere
25
Progress Toward Hepatitis B Control and Elimination of Mother-to-Child Transmission of Hepatitis B Virus - World Health Organization African Region, 2016-2021
Morbidity and Mortality Weekly Report (MMWR), 21.07.2023
Tilføjet 21.07.2023
This report describes progress towards hepatitis B control and elimination in the World Health Organization African region.
Læs mere
26
Diagnosis of Viral Hepatitis Is Still a Major Challenge
Medscape Infectious Diseases, 15.07.2023
Tilføjet 15.07.2023
World Hepatitis Day is an opportunity to remind people of the impact of viral hepatitis and to offer information that can help prevent, diagnose, and treat these diseases, said one expert. Medscape Medical News
Læs mere
27
Updated Operational Guidance for Implementing CDC's Recommendations on Testing for Hepatitis C Virus Infection
Morbidity and Mortality Weekly Report (MMWR), 14.07.2023
Tilføjet 14.07.2023
This report describes new CDC guidance for completing hepatitis C virus testing.
Læs mere
28
A Decade After First DAA, Only 1 in 3 Are HCV Free
Medscape Infectious Diseases, 12.07.2023
Tilføjet 12.07.2023
Patients with hepatitis C virus (HCV) infection face barriers at every step, from diagnosis to accessing breakthrough direct-acting antiviral (DAA) medications, experts say. Medscape Medical News
Læs mere
29
Bulevirtide for Hep D: Phase 3 Data Now Published in NEJM
Medscape Infectious Diseases, 8.07.2023
Tilføjet 8.07.2023
Bulevirtide, an investigational, first-in-class hepatitis delta virus entry-inhibitor, significantly reduced viral load and normalized liver enzymes in patients. Medscape Medical News
Læs mere
30
Hepatitis C Virus Clearance Cascade - United States, 2013-2022
Morbidity and Mortality Weekly Report (MMWR), 1.07.2023
Tilføjet 1.07.2023
This report describes progress towards achieving hepatitis C viral clearance by 2030.
Læs mere